Results 171 to 180 of about 2,387 (195)

Nirsevimab: The Hidden Costs

Hospital Pediatrics
Samantha, Neumann, Brian, Alverson
openaire   +2 more sources

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine, 2022
William J Muller, Michael E Abram, Amanda Leach   +2 more
exaly  

Nirsevimab

Reactions Weekly
openaire   +2 more sources

Nirsevimab for RSV Prophylaxis in Healthy Infants

AAP Grand Rounds, 2022
openaire   +1 more source

Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)

Anales De Pediatría (English Edition), 2023
Ana Belén Jiménez
exaly  

Nirsevimab for Prevention of RSV Hospitalizations in Infants

New England Journal of Medicine
Saul N, Faust, Simon B, Drysdale, Natalya C, Vassilouthis   +2 more
openaire   +3 more sources

Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts

Pediatrics
Claire, Abraham, Jon, Hatoun, Emily Trudell, Correa, Naveed, Rabbani, Louis, Vernacchio   +4 more
openaire   +2 more sources

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France

EClinicalMedicine
Francois Dubos
exaly  

Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis

The Lancet Child & Adolescent Health
Assad, Zein, Papenburg, Jesse, Ouldali, Naïm   +2 more
openaire   +3 more sources

Factors Associated With Nirsevimab Uptake in Healthy Newborns

Hospital Pediatrics
Elena, Aragona, Veronika, Shabanova, Jaspreet, Loyal   +2 more
openaire   +2 more sources